Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masupirdine for Agitation in Alzheimer's Dementia
NCT05397639Phase 3Active, not recruiting
- Sponsor
- Suven Life Sciences
- Start
- Nov 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of masupirdine in agitation, sponsored by Suven Life Sciences. Started Nov 2022; status: active, not recruiting.
02
Drugs
masupirdine
03
Conditions
agitation
Beyond the preview
Go deeper on NCT05397639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05397639.